ES2095956T3 - Conjugados antigeno-anticuerpo. - Google Patents

Conjugados antigeno-anticuerpo.

Info

Publication number
ES2095956T3
ES2095956T3 ES91916937T ES91916937T ES2095956T3 ES 2095956 T3 ES2095956 T3 ES 2095956T3 ES 91916937 T ES91916937 T ES 91916937T ES 91916937 T ES91916937 T ES 91916937T ES 2095956 T3 ES2095956 T3 ES 2095956T3
Authority
ES
Spain
Prior art keywords
antigen
antibody conjugates
deputy
diseases
anypropriate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91916937T
Other languages
English (en)
Inventor
Donald William Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909021210A external-priority patent/GB9021210D0/en
Priority claimed from GB919110444A external-priority patent/GB9110444D0/en
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Application granted granted Critical
Publication of ES2095956T3 publication Critical patent/ES2095956T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LAS ENFERMEDADES ATRIBUIBLES A UNA RESPUESTA INMUNE PREDOMINANTEMENTE MEDIATIZADA POR LAS CELULAS, DE FORMA NOTABLE LAS ENFERMEDADES AUTOINMUNES, PUEDEN SUPRIMIRSE ADMINISTRANDO UN NUEVO CONJUGADO DE UN ANTIGENO APROPIADO, NOTABLEMENTE UN AUTOANTIGENO, CON ANTICUERPOS PARA UNA MOLECULA DE LA SUPERFICIE CELULAR B APROPIADA, TAL COMO LA IGD.
ES91916937T 1990-09-28 1991-09-24 Conjugados antigeno-anticuerpo. Expired - Lifetime ES2095956T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909021210A GB9021210D0 (en) 1990-09-28 1990-09-28 Antigen-antibody conjugates
GB919110444A GB9110444D0 (en) 1991-05-14 1991-05-14 Antigen-antibody conjugates ii

Publications (1)

Publication Number Publication Date
ES2095956T3 true ES2095956T3 (es) 1997-03-01

Family

ID=26297729

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91916937T Expired - Lifetime ES2095956T3 (es) 1990-09-28 1991-09-24 Conjugados antigeno-anticuerpo.

Country Status (6)

Country Link
EP (1) EP0550544B1 (es)
JP (1) JPH06501464A (es)
AU (1) AU654679B2 (es)
DE (1) DE69123256T2 (es)
ES (1) ES2095956T3 (es)
WO (1) WO1992006120A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536924A (ja) * 2006-04-27 2009-10-22 ノーザン シドニー アンド セントラル コースト エリア ヘルス サービス ヘルパーｔ細胞が媒介する免疫応答の調節方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666080B1 (en) * 1987-06-24 2004-01-21 Brigham & Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
CA2015515C (en) * 1990-01-03 1999-12-07 Jean-Marie Saint-Remy Pharmaceutical compositions containing antigen-antibody complexes and uses therefor

Also Published As

Publication number Publication date
EP0550544B1 (en) 1996-11-20
WO1992006120A1 (en) 1992-04-16
JPH06501464A (ja) 1994-02-17
AU8618791A (en) 1992-04-28
EP0550544A1 (en) 1993-07-14
DE69123256D1 (de) 1997-01-02
AU654679B2 (en) 1994-11-17
DE69123256T2 (de) 1997-06-12

Similar Documents

Publication Publication Date Title
IT7828930A0 (it) Derivati di 2,6-diamminonebularine ad azione farmacologica.
IT8119611A0 (it) Elastomeri ottenuti mediante stampaggio ad iniezione con reazione, dotati di una superiore stabilita' dimensionale atemperatura elevata.
IT7919369A0 (it) Derivati della tienoidantoina ad azione terapeutica.
NL7809231A (nl) Houder met een uit op elkaar aasluitende betonplaten samengestelde, voorgespannen omtrekswand.
IT1110037B (it) Struttura ad invertitore,ad elementi mos complementari
IT7885554A0 (it) Perfezionamenti al procedimento di formatura di corpi cavi.
ES2095956T3 (es) Conjugados antigeno-anticuerpo.
IT1135102B (it) Traduttore ad anello di cotocircuito con almeno una foglia ad elevata permeabilita'
NL189156C (nl) Schakeling met een gestabiliseerde uitgangsstroom.
IT7922720A0 (it) Derivati 4-ammino-2-piperidinochinazolinici ad azione terapeutica.
AR025088A1 (es) Un te negro de hojas
IT8221942A0 (it) Accessorio sanitario batteria con commutazione vasca da bagno-doccia.
DE3884419D1 (de) Alkohole und ether mit cyclododecyl- und cyclododecenylgruppen, deren herstellung und verwendung als duftstoffe.
IT1141134B (it) Derivati peptidici ad azione farmacologica
IT8467709A0 (it) Procedimento per la fabbricazione di corpi cavi precompressi di calcestruzzo particolarmente tubi di calcestruzzo precompresso corpi cavi fabbricati con il procedimento particolarmente tubi di calcestruzzo precompresso nonche dispositivo per l attuazione del procedimento
DK1330417T3 (da) Glasvaremaskine
CH554665A (de) Badeinrichtung, insbesondere fuer bewegungsbehinderte personen.
ECSP003761A (es) Compuestos heterociclicos sililados
SU655856A1 (ru) Торцевое уплотнение
IT7822748A0 (it) Gruppo di pompaggio di additivo per macchine lavapiatti, e macchine lavapiatti fornite di tale gruppo.
SE9900693D0 (sv) Novel process
IT1160414B (it) Benzoisotiazolo-1,1-diossidi ad azione anti-infiammatoria
IT7921115A0 (it) Derivati di ciclitolammine ad azione farmaceutica.
DE69113874T2 (de) Zyklische Ether-Derivate.
JPS53109461A (en) Transistor amplififer for microwave

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 550544

Country of ref document: ES